A Food and Drug Administration advisory panel expressed concerns over the use of selective serotonin reuptake inhibitors (SSRIs) during pregnancy, discussing potential risks to fetal neurodevelopment and questioning the net benefit. The panel did not reach consensus on regulatory actions but suggested more stringent drug labeling. FDA Commissioner Martin Makary highlighted rising antidepressant usage and emphasized the need to explore root causes of increased prescribing trends. This review follows similar FDA scrutiny of hormonal therapies and mental health drug policies.